{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:52:01Z","timestamp":1781589121760,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Liver cirrhosis causes physiological and pharmacokinetic alterations that complicate antihypertensive therapy, in the presence of portal and arterial hypertension. This study evaluated the efficacy and safety of PBPK-guided dosing of carvedilol and nebivolol in cirrhotic patients. First, PBPK models were validated using clinical pharmacokinetic data from healthy volunteers and optimized for cirrhosis, then applied to simulate untested cirrhotic populations and estimate unbound plasma exposure across disease stages. Second, a prospective, open-label, parallel randomized pilot study enrolled 44 cirrhotic patients (Child-Pugh; CP-A or B) with arterial hypertension, who received PBPK-guided doses of carvedilol or nebivolol, with 3 months of follow-up including monthly monitoring of adverse events, blood pressure, heart rate, portal hemodynamics by Doppler ultrasound, and laboratory safety parameters. The model predicted dose reductions of carvedilol 25\u00a0mg once daily and nebivolol 10\u00a0mg once daily to 11.26\u00a0mg and 4.98\u00a0mg in mild cirrhosis, 5.52\u00a0mg and 2.98\u00a0mg in moderate cirrhosis, and 1.99\u00a0mg and 1.23\u00a0mg in severe cirrhosis. Following administration of doses as close as possible to the PBPK-guided doses in CP A and B, both agents were well tolerated, effectively reducing blood pressure and heart rate without significant changes in hepatic and renal parameters. Portal hemodynamics and platelet count improved in both groups, with carvedilol showing greater effects; adverse events were mild and more frequent with carvedilol. While both drugs controlled blood pressure, carvedilol improved portal hemodynamics more. PBPK-guided dosing addressed pharmacokinetic changes, but pharmacodynamic differences between CP-A and CP-B persisted due to disease progression.<\/jats:p>","DOI":"10.1038\/s41598-026-56578-3","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T01:14:26Z","timestamp":1781572466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study"],"prefix":"10.1038","volume":"16","author":[{"given":"Mai","family":"Tarek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Biomy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"El-Khateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"56578_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.mcna.2021.12.001","volume":"106","author":"R Wilson","year":"2022","unstructured":"Wilson, R., Williams, D. M. & Cirrhosis Med. Clin. North. Am. 106, 437\u2013446 (2022).","journal-title":"Med. Clin. North. Am."},{"key":"56578_CR2","doi-asserted-by":"publisher","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","volume":"3","author":"Y Iwakiri","year":"2021","unstructured":"Iwakiri, Y. & Trebicka, J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep. 3, 100316 (2021).","journal-title":"JHEP Rep."},{"key":"56578_CR3","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","volume":"26","author":"LS Gunarathne","year":"2020","unstructured":"Gunarathne, L. S., Rajapaksha, H., Shackel, N., Angus, P. W. & Herath, C. B. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics. World J. Gastroenterol. 26, 6111\u20136140 (2020).","journal-title":"World J. Gastroenterol."},{"key":"56578_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1586\/egh.12.83","volume":"7","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti, A., Seijo, S., Reverter, E. & Bosch, J. Assessing portal hypertension in liver diseases. Expert Rev. Gastroenterol. Hepatol. 7, 141\u2013155 (2013).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"56578_CR5","doi-asserted-by":"publisher","unstructured":"El Gazzar, N. A. E. N., Ali, L. A., Yousef, M. & Elfert, A. Prevalence of arterial hypertension in liver cirrhosis and correlation with the severity of liver disease. Int. J. Health Sci. (Qassim). 12305\u201312313. https:\/\/doi.org\/10.53730\/ijhs.v6nS5.11363 (2022).","DOI":"10.53730\/ijhs.v6nS5.11363"},{"key":"56578_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/1319-3767.45067","volume":"15","author":"P Prabhu","year":"2009","unstructured":"Prabhu, P., Srinivasan, R. & Jayanthi, V. Prevalence of Arterial Hypertension in Cirrhosis of Liver. Saudi J. Gastroenterol. 15, 65 (2009).","journal-title":"Saudi J. Gastroenterol."},{"key":"56578_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3748\/wjg.v12.i5.678","volume":"12","author":"JH Henriksen","year":"2006","unstructured":"Henriksen, J. H. & Moller, S. Liver cirrhosis and arterial hypertension. World J. Gastroenterol. 12, 678 (2006).","journal-title":"World J. Gastroenterol."},{"key":"56578_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"G Levine","year":"2018","unstructured":"Levine, G. et al. (ed, N.) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention,Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task \u2026. Hypertension 71 1269\u20131324 (2018).","journal-title":"Hypertension"},{"key":"56578_CR9","unstructured":"Singh, S. & Preuss, C. V. Carvedilol. StatPearlsStatPearls Publishing, (2025)."},{"key":"56578_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2021","unstructured":"de Franchis, R. et al. Baveno VII \u2013 Renewing consensus in portal hypertension. J. Hepatol. 76, 959 (2021).","journal-title":"J. Hepatol."},{"key":"56578_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65, 310\u2013335 (2017).","journal-title":"Hepatology"},{"key":"56578_CR12","doi-asserted-by":"publisher","first-page":"e010902","DOI":"10.1136\/bmjopen-2015-010902","volume":"6","author":"T Li","year":"2016","unstructured":"Li, T. et al. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 6, e010902 (2016).","journal-title":"BMJ Open."},{"key":"56578_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/1753944709104496","volume":"3","author":"A Maffei","year":"2009","unstructured":"Maffei, A. & Lembo, G. Nitric oxide mechanisms of nebivolol. Ther. Adv. Cardiovasc. Dis. 3, 317\u2013327 (2009).","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"56578_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/vhrm.2006.2.3.303","volume":"2","author":"R Weiss","year":"2006","unstructured":"Weiss, R. & Nebivolol A Novel Beta-Blocker with Nitric Oxide-Induced Vasodilatation. Vasc Health Risk Manag. 2, 303 (2006).","journal-title":"Vasc Health Risk Manag"},{"key":"56578_CR15","first-page":"467","volume":"49","author":"V Silkauskait\u0117","year":"2013","unstructured":"Silkauskait\u0117, V. et al. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. Med. (Kaunas). 49, 467\u2013473 (2013).","journal-title":"Med. (Kaunas)"},{"key":"56578_CR16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","volume":"57","author":"JC Garc\u00eda-Pag\u00e1n","year":"2012","unstructured":"Garc\u00eda-Pag\u00e1n, J. C., Gracia-Sancho, J. & Bosch, J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J. Hepatol. 57, 458\u2013461 (2012).","journal-title":"J. Hepatol."},{"key":"56578_CR17","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00261-024-04568-2","volume":"50","author":"G Ferraioli","year":"2024","unstructured":"Ferraioli, G. & Barr, R. G. Ultrasound evaluation of chronic liver disease. Abdom. Radiol. 50, 1158\u20131170 (2024).","journal-title":"Abdom. Radiol."},{"key":"56578_CR18","first-page":"240","volume":"11","author":"K Usharani","year":"2017","unstructured":"Usharani, K. & Srinivas, T. Assessment of Portal Hypertension Using High-Resolution Ultrasonography and Colour Doppler. Res. J. Med. Sci. 11, 240 (2017).","journal-title":"Res. J. Med. Sci."},{"key":"56578_CR19","unstructured":"Bertici, S. Non-invasive Portal Hypertension Diagnosis in HBV- and HCV-related Cirrhosis: A Review. J. Hypertens 13, 450 (2024)."},{"key":"56578_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland, M., Peck, C. & Tucker, G. Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annu. Rev. Pharmacol. Toxicol. 51, 45\u201373 (2011).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"56578_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/clpt.2014.46","volume":"95","author":"V Sinha","year":"2014","unstructured":"Sinha, V., Zhao, P., Huang, S. M. & Zineh, I. Physiologically Based Pharmacokinetic Modeling: From Regulatory Science to Regulatory Policy. Clin. Pharmacol. Ther. 95, 478\u2013480 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"56578_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1208\/s12248-012-9446-2","volume":"15","author":"HM Jones","year":"2013","unstructured":"Jones, H. M., Mayawala, K. & Poulin, P. Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches. AAPS J. 15, 377\u2013387 (2013).","journal-title":"AAPS J."},{"key":"56578_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/psp4.52","volume":"4","author":"M Rowland","year":"2015","unstructured":"Rowland, M., Lesko, L. & Rostami-Hodjegan, A. Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making. CPT Pharmacometrics Syst. Pharmacol. 4, 313\u2013315 (2015).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"56578_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","volume":"47","author":"AN Edginton","year":"2008","unstructured":"Edginton, A. N. & Willmann, S. Physiology-Based Simulations of a Pathological Condition. Clin. Pharmacokinet. 47, 743\u2013752 (2008).","journal-title":"Clin. Pharmacokinet."},{"key":"56578_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/bdd.2257","volume":"42","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb, E. et al. Physiological\u2010based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20\u2010years; in\u2010depth analysis of applications, organizations, and platforms. Biopharm. Drug Dispos. 42, 107\u2013117 (2021).","journal-title":"Biopharm. Drug Dispos."},{"key":"56578_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1208\/s12249-008-9055-7","volume":"9","author":"T Loftsson","year":"2008","unstructured":"Loftsson, T., Vogensen, S. B., Desbos, C., Jansook, P. & Carvedilol Solubilization and cyclodextrin complexation: A technical note. AAPS PharmSciTech. 9, 425\u2013430 (2008).","journal-title":"AAPS PharmSciTech"},{"key":"56578_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s13318-016-0353-2","volume":"42","author":"MF Rasool","year":"2017","unstructured":"Rasool, M. F., Khalil, F. & L\u00e4er, S. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach. Eur. J. Drug Metab. Pharmacokinet. 42, 383\u2013396 (2017).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"56578_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei, M. et al. Population-Based Mechanistic Prediction of Oral Drug Absorption. AAPS J. 11, 225\u2013237 (2009).","journal-title":"AAPS J."},{"key":"56578_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers, T. & Rowland, M. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes. Pharm. Res. 24, 918\u2013933 (2007).","journal-title":"Pharm. Res."},{"key":"56578_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238\u20131257 (2006).","journal-title":"J. Pharm. Sci."},{"key":"56578_CR31","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/jps.20073","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy, L. M. Volume of Distribution at Steady State for a Linear Pharmacokinetic System with Peripheral Elimination. J. Pharm. Sci. 93, 1628\u20131640 (2004).","journal-title":"J. Pharm. Sci."},{"key":"56578_CR32","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-015-0435-5","volume":"75","author":"J Fongemie","year":"2015","unstructured":"Fongemie, J. & Felix-Getzik, E. A. Review of Nebivolol Pharmacology and Clinical Evidence. Drugs 75, 1349 (2015).","journal-title":"Drugs"},{"key":"56578_CR33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/chir.23595","volume":"35","author":"CM Toma","year":"2023","unstructured":"Toma, C. M., Imre, S., Farczadi, L., Ion, V. & Marc, G. Enantioselective binding of carvedilol to human serum albumin and alpha-1-acid glycoprotein. Chirality 35, 779\u2013792 (2023).","journal-title":"Chirality"},{"key":"56578_CR34","first-page":"970","volume":"25","author":"HG Oldham","year":"1997","unstructured":"Oldham, H. G. & Clarke, S. E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R (+)-and S (\u2013)-carvedilol. Drug Metab. Dispos. 25, 970\u2013977 (1997).","journal-title":"Drug Metab. Dispos."},{"key":"56578_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1248\/bpb.35.151","volume":"35","author":"Y Takekuma","year":"2012","unstructured":"Takekuma, Y., Yagisawa, K. & Sugawara, M. Mutual Inhibition between Carvedilol Enantiomers during Racemate Glucuronidation Mediated by Human Liver and Intestinal Microsomes. Biol. Pharm. Bull. 35, 151\u2013163 (2012).","journal-title":"Biol. Pharm. Bull."},{"key":"56578_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.5414\/CPP44344","volume":"44","author":"W Gielen","year":"2006","unstructured":"Gielen, W., Cleophas, T. J. & Agrawal, R. Nebivolol: a review of its clinical and pharmacological characteristics. Int. J. Clin. Pharmacol. Ther. 44, 344\u2013357 (2006).","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"56578_CR37","doi-asserted-by":"publisher","first-page":"e70148","DOI":"10.1002\/jcph.70148","volume":"66","author":"M Tarek","year":"2026","unstructured":"Tarek, M., Amin, A. A., Biomy, R. & Abdelkawy, K. El-Khateeb, E. Using Physiologically Based Pharmacokinetic Modeling and Simulations to Predict Antihypertensive Drug Doses in Cirrhotic Patients. J. Clin. Pharmacol. 66, e70148 (2026).","journal-title":"J. Clin. Pharmacol."},{"key":"56578_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3892\/br.2013.60","volume":"1","author":"F MENG","year":"2013","unstructured":"MENG, F. et al. Assessment of the value of serum cholinesterase as a liver function test for cirrhotic patients. Biomed. Rep. 1, 265\u2013268 (2013).","journal-title":"Biomed. Rep."},{"key":"56578_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2165\/00003495-198800366-00026","volume":"36","author":"G Neugebauer","year":"1988","unstructured":"Neugebauer, G., Gabor, M. & Reiff, K. Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis. Drugs 36, 148\u2013154 (1988).","journal-title":"Drugs"},{"key":"56578_CR40","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","volume":"54","author":"MF Rasool","year":"2015","unstructured":"Rasool, M. F., Khalil, F. & L\u00e4er, S. A. Physiologically Based Pharmacokinetic Drug\u2013Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clin. Pharmacokinet. 54, 943\u2013962 (2015).","journal-title":"Clin. Pharmacokinet."},{"key":"56578_CR41","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/aps.2012.103","volume":"33","author":"G Li","year":"2012","unstructured":"Li, G. et al. Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling. Acta Pharmacol. Sin. 33, 1359\u20131371 (2012).","journal-title":"Acta Pharmacol. Sin"},{"key":"56578_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2165\/00003495-198800366-00015","volume":"36","author":"JJ McPhillips","year":"1988","unstructured":"McPhillips, J. J., Schwemer, G. T., Scott, D. I., Zinny, M. & Patterson, D. Effects of Carvedilol on Blood Pressure in Patients with Mild to Moderate Hypertension. Drugs 36, 82\u201391 (1988).","journal-title":"Drugs"},{"key":"56578_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1592\/phco.24.1.94.34805","volume":"24","author":"BA Hemstreet","year":"2004","unstructured":"Hemstreet, B. A. Evaluation of carvedilol for the treatment of portal hypertension. Pharmacotherapy 24, 94\u2013104 (2004).","journal-title":"Pharmacotherapy"},{"key":"56578_CR44","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/hep.23045","volume":"50","author":"D Tripathi","year":"2009","unstructured":"Tripathi, D. et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 50, 825\u2013833 (2009).","journal-title":"Hepatology"},{"key":"56578_CR45","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"WM Association","year":"2013","unstructured":"Association, W. M. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"56578_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/03602532.2023.2271195","volume":"55","author":"N Hanif","year":"2023","unstructured":"Hanif, N. et al. Clinical pharmacokinetics of nebivolol: a systematic review. Drug Metab. Rev. 55, 428\u2013440 (2023).","journal-title":"Drug Metab. Rev."},{"key":"56578_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/jps.2600790704","volume":"79","author":"M Fujimaki","year":"1990","unstructured":"Fujimaki, M., Murakoshi, Y. & Hakusui, H. Assay and Disposition of Carvedilol Enantiomers in Humans and Monkeys: Evidence of Stereoselective Presystemic Metabolism. J. Pharm. Sci. 79, 568\u2013572 (1990).","journal-title":"J. Pharm. Sci."},{"key":"56578_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ajh\/7.2.129","volume":"7","author":"LM Ruilope","year":"1994","unstructured":"Ruilope, L. M. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. Am. J. Hypertens. 7, 129\u2013136 (1994).","journal-title":"Am. J. Hypertens."},{"issue":"Suppl 4","key":"56578_CR49","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1097\/00005344-199118041-00008","volume":"18","author":"S Hall","year":"1991","unstructured":"Hall, S. et al. A comparative study of carvedilol, slow-release nifedipine, and atenolol in the management of essential hypertension. J. Cardiovasc. Pharmacol. 18 (Suppl 4), S35\u2013S38 (1991).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"56578_CR50","first-page":"188","volume":"34","author":"O Hilas","year":"2009","unstructured":"Hilas, O. & Ezzo, D. Nebivolol (Bystolic), a Novel Beta Blocker for Hypertension. Pharm. Ther. 34, 188 (2009).","journal-title":"Pharm. Ther."},{"key":"56578_CR51","doi-asserted-by":"crossref","unstructured":"Erdo\u01e7an, O. et al. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. Anadolu Kardiyol Derg 11, 310\u2013313 (2011).","DOI":"10.5152\/akd.2011.081"},{"key":"56578_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14366\/usg.15020","volume":"35","author":"P Iranpour","year":"2016","unstructured":"Iranpour, P. et al. Altered Doppler flow patterns in cirrhosis patients: an overview. Ultrasonography 35, 3\u201312 (2016).","journal-title":"Ultrasonography"},{"key":"56578_CR53","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/liv.12101","volume":"33","author":"T Reiberger","year":"2013","unstructured":"Reiberger, T. et al. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int. 33, 561\u2013568 (2013).","journal-title":"Liver Int."},{"key":"56578_CR54","first-page":"36","volume":"7","author":"I Ahmed","year":"2016","unstructured":"Ahmed, I., Husain, A., Waqas, M. & Hanif, F. Comparison of the efficacy of carvedilol and propranolol in the secondary prevention of esophageal variceal bleeding. J. Univ. Med. Dent. Coll. 7, 36\u201342 (2016).","journal-title":"J. Univ. Med. Dent. Coll."},{"key":"56578_CR55","first-page":"986","volume":"13","author":"VM Fern\u00e1ndez-Garibay","year":"2025","unstructured":"Fern\u00e1ndez-Garibay, V. M. et al. The Mechanisms behind Thrombocytopenia in Patients with Portal Hypertension and Chronic Liver Disease. J. Clin. Transl Hepatol. 13, 986\u2013991 (2025).","journal-title":"J. Clin. Transl Hepatol."},{"key":"56578_CR56","first-page":"2070","volume":"26","author":"MJ Mujahid","year":"2019","unstructured":"Mujahid, M. J. et al. Improvement in Thrombocytopenia after Carvedilol use in Hepatitis C cirrhotic patients. Prof. Med. J. 26, 2070\u20132074 (2019).","journal-title":"Prof. Med. J."},{"issue":"10","key":"56578_CR57","first-page":"1530","volume":"10, Page 1530","author":"RE Scharf","year":"2021","unstructured":"Scharf, R. E. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management. J. Clin. Med. 2021. 10, Page 1530 (10), 1530 (2021).","journal-title":"J. Clin. Med. 2021"},{"key":"56578_CR58","doi-asserted-by":"crossref","unstructured":"Maharaj, S. et al. Severe carvedilol toxicity without overdose - caution in cirrhosis. Clin Hypertens 23, 25 (2017).","DOI":"10.1186\/s40885-017-0083-z"},{"key":"56578_CR59","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2165\/00003495-199345020-00006","volume":"45","author":"D McTavish","year":"1993","unstructured":"McTavish, D., Campoli-Richards, D. & Sorkin, E. M. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45, 232\u2013258 (1993).","journal-title":"Drugs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56578-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56578-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:00:09Z","timestamp":1781586009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56578-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56578"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56578-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eman El-Khateeb is an employee of Certara Predictive Technologies and may hold shares in Certara. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The purpose and nature of the study were explained to all participants, and they were informed of their right to withdraw from the study at any time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Accordance Approval"}},{"value":"This study was approved by the Scientific Research Ethics Committee (Institutional Review Board) of Kafrelsheikh University, Egypt (Approval No. KFSIRB200-126).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval Statement"}},{"value":"The study was registered retrospectively at ClinicalTrials.gov (Identifier: NCT07397481) on 4 February 2026.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration trial"}}],"article-number":"18663"}}